HC Wainwright Estimates Ardelyx's Q2 Earnings (NASDAQ:ARDX)

Ardelyx, Inc. (NASDAQ:ARDX - Free Report) - Stock analysts at HC Wainwright issued their Q2 2025 earnings per share (EPS) estimates for shares of Ardelyx in a report issued on Wednesday, June 18th. HC Wainwright analyst M. Caufield forecasts that the biopharmaceutical company will post earnings per share of ($0.14) for the quarter. HC Wainwright has a "Buy" rating and a $10.00 price target on the stock. The consensus estimate for Ardelyx's current full-year earnings is ($0.18) per share. HC Wainwright also issued estimates for Ardelyx's Q3 2025 earnings at ($0.08) EPS, Q4 2025 earnings at ($0.04) EPS, FY2025 earnings at ($0.44) EPS, FY2026 earnings at ($0.19) EPS, FY2027 earnings at $0.14 EPS, FY2028 earnings at $0.63 EPS and FY2029 earnings at $1.15 EPS.

Ardelyx (NASDAQ:ARDX - Get Free Report) last posted its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.07). Ardelyx had a negative return on equity of 34.45% and a negative net margin of 14.86%. The business had revenue of $74.11 million during the quarter, compared to the consensus estimate of $79.40 million. During the same period in the previous year, the business posted ($0.11) EPS. The firm's revenue for the quarter was up 61.1% on a year-over-year basis.

A number of other equities research analysts also recently commented on the company. Piper Sandler upgraded Ardelyx to a "hold" rating in a research report on Wednesday, March 12th. Cantor Fitzgerald raised Ardelyx to a "strong-buy" rating in a research note on Tuesday, March 4th. Scotiabank initiated coverage on Ardelyx in a research note on Friday, March 7th. They issued a "sector outperform" rating and a $15.00 price objective on the stock. Citigroup dropped their price objective on Ardelyx from $11.00 to $10.00 and set a "buy" rating on the stock in a research note on Friday, May 2nd. Finally, Raymond James Financial cut Ardelyx from a "strong-buy" rating to an "outperform" rating and set a $11.00 target price on the stock. in a research report on Friday, May 2nd. One analyst has rated the stock with a sell rating, one has issued a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $10.89.

Ardelyx Trading Down 1.4%

Shares of NASDAQ:ARDX opened at $3.56 on Monday. The stock has a 50 day moving average of $4.10 and a 200 day moving average of $4.82. The company has a market cap of $851.77 million, a PE ratio of -16.18 and a beta of 0.60. The company has a current ratio of 4.12, a quick ratio of 3.81 and a debt-to-equity ratio of 1.04. Ardelyx has a 12-month low of $3.21 and a 12-month high of $8.06.

Insider Activity

In other Ardelyx news, insider Laura A. Williams sold 6,421 shares of the business's stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $4.08, for a total value of $26,197.68. Following the transaction, the insider now owns 402,583 shares in the company, valued at $1,642,538.64. The trade was a 1.57% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director David M. Mott purchased 200,000 shares of the company's stock in a transaction on Monday, June 16th. The stock was purchased at an average price of $3.63 per share, for a total transaction of $726,000.00. Following the purchase, the director now directly owns 2,896,871 shares of the company's stock, valued at $10,515,641.73. This trade represents a 7.42% increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders acquired 881,377 shares of company stock valued at $3,402,411 and sold 166,809 shares valued at $708,914. Company insiders own 4.80% of the company's stock.

Institutional Investors Weigh In On Ardelyx

Several hedge funds have recently made changes to their positions in the company. Janus Henderson Group PLC raised its holdings in shares of Ardelyx by 13.3% during the 4th quarter. Janus Henderson Group PLC now owns 24,387,941 shares of the biopharmaceutical company's stock valued at $123,587,000 after purchasing an additional 2,858,061 shares in the last quarter. Vanguard Group Inc. boosted its position in Ardelyx by 4.4% in the first quarter. Vanguard Group Inc. now owns 14,997,234 shares of the biopharmaceutical company's stock valued at $73,636,000 after buying an additional 634,575 shares in the last quarter. Millennium Management LLC boosted its position in Ardelyx by 118.2% in the first quarter. Millennium Management LLC now owns 6,465,262 shares of the biopharmaceutical company's stock valued at $31,744,000 after buying an additional 3,501,782 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Ardelyx by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 5,509,730 shares of the biopharmaceutical company's stock worth $27,941,000 after acquiring an additional 21,988 shares during the last quarter. Finally, Nuveen LLC bought a new position in shares of Ardelyx in the first quarter worth about $16,735,000. Hedge funds and other institutional investors own 58.92% of the company's stock.

Ardelyx Company Profile

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.